Mandate

Vinge has advised CELLINK in connection with directed issues of SEK 3 billion

Vinge has advised CELLINK AB (publ) in connection with a directed issue of covertibles of SEK 1.5 billion and a directed issue of B-shares of SEK 1.5 billion, in total SEK 3 billion.

The convertibles and the shares have been offered by way of an accelerated bookbuilding process arranged by Citigroup Global Markets, J.P. Morgan and Carnegie Investment Bank. The convertibles and shares were subscribed for by Swedish and international institutional investors.

Vinge’s team has consisted of Anders Strid, Edin Agic, Hampus Olsson, Linus Adolfsson and Maria Schultzberg (tax). Sullivan & Cromwell has advised Cellink in relation to English and US laws.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025